Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MDC-007 is an actively targeted lipid nanoparticle (LNP) delivery system developed by MediciBio. It utilizes antibody or aptamer ligand conjugation to achieve cell-specific delivery of mRNA or siRNA payloads. The platform is designed to target a variety of cell types, including cancer cells and immune cells such as T cells, monocytes, macrophages, and natural killer (NK) cells. Its primary applications include cancer therapies, immunotherapies, and the generation of in vivo CAR therapies, where genetic instructions are delivered directly to immune cells to enable targeted anti-tumor activity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MDC-007.